An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
about
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inceptionDescribing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study.Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkersModeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database.Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries.A focus on structural brain imaging in the Alzheimer's disease neuroimaging initiative2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative.Trajectories of dementia-related cognitive decline in a large mental health records derived patient cohortAlzheimer's disease progression model based on integrated biomarkers and clinical measures.Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis.Total cholesterol and neuropsychiatric symptoms in Alzheimer's disease: the impact of total cholesterol level and gender.Studying ventricular abnormalities in mild cognitive impairment with hyperbolic Ricci flow and tensor-based morphometryClinical pharmacology = disease progression + drug actionNew scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials.Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer's Disease - Prospective Use of Novel Composite ScalesDisease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypesAdvances in designs for Alzheimer's disease clinical trials.Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's diseaseA review of disease progression models of Parkinson's disease and applications in clinical trialsThe ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI.Disease progression and neuroscience.The future is now: model-based clinical trial design for Alzheimer's disease.Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression.Disease Progression Modeling: Key Concepts and Recent DevelopmentsA Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly SubjectsStudying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta.Evaluation of Alzheimer's disease progression based on clinical dementia rating scale with missing responses and covariates.The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments.Harnessing the informatics revolution for neuroscience drug R&D.An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.
P2860
Q27006831-F15DB1FA-97ED-4A92-A3E2-FC9FC42388D1Q27333816-50FF9F88-9C9E-4867-A8A9-A40C010C18C2Q28542010-44305316-1BB2-41F6-9E77-0DF0FCAC4723Q30567951-D5B000E1-2AAF-406D-89BD-541634466F44Q30621152-0B411F8F-3A94-48EA-A29B-0282B49B022CQ30724134-650B2535-F3D4-437F-8EE6-2B91B7A3CD48Q30971403-787135DD-E636-4A59-8228-DA09D4119C9DQ33726385-41F85502-6381-4675-98F8-60550CFC0657Q33773036-0882A7C9-F30C-4CDD-8DDD-21F9E48B68C0Q34138353-6EC231C9-5BE0-4C52-ABC5-89D8CD369C5BQ34347396-95EC68D5-5F13-4603-8D0D-4112ECEDB140Q34364200-26411CEF-80AF-41E5-BAA0-57B7F6CD0E16Q34615211-A5CA3CD8-B4CB-4B41-B18A-583864F45E1BQ34953659-8775E5DA-3D42-44A1-A005-F6966FDAD79FQ36274037-6A865E59-4558-46FC-B590-4237A7A6E8A7Q36558187-0980FC6A-322E-4B82-8639-BFEB2835C11AQ36562471-9B53C4A6-B334-48A6-861D-CD3F6BD10780Q36576472-501C86CC-00E2-443A-9162-0576EC2286DEQ36780771-4D438460-FE10-4EC9-BF2B-8CCAA2D76A0DQ37062838-39635EE7-CF52-42C3-8FE5-DD2D4655827AQ37068194-4689A438-3104-48FA-9F1F-A65E16975C66Q37279402-1284B105-B430-433E-89B3-99825533DA52Q38099584-20D2B5E9-D1C7-42D1-90E2-B89AEEE74C85Q38351053-3C83231C-F6D7-46E9-BCA8-22A044917507Q38759319-C255CECC-7E91-4A1F-8589-C66B4AF92341Q41639443-7C4D3808-EAEA-4A21-B475-1C86AC45CDBFQ42363855-2F16BD87-D223-4FD6-BE42-5D4AD9447E7BQ42621653-9C36A828-109F-4DB7-B1C7-AC91645DD0E3Q47367332-B4AE8771-803F-4F2F-8D2A-082BD304D235Q47555369-2222D41C-0DBE-4276-8216-CF4E77544AD2Q50630085-023E2120-001A-47A9-9987-DA812AC6ECE2Q53356299-D64DCBC2-C2D8-4330-A1AE-AF56D52464ABQ54942565-492E5668-7AFF-4287-8F71-272AFCAA14C0Q55411843-112D111C-A5D3-42B0-83A9-DD5DC00973F6
P2860
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
An improved model for disease ...... sease neuroimaging initiative.
@en
An improved model for disease ...... sease neuroimaging initiative.
@nl
type
label
An improved model for disease ...... sease neuroimaging initiative.
@en
An improved model for disease ...... sease neuroimaging initiative.
@nl
prefLabel
An improved model for disease ...... sease neuroimaging initiative.
@en
An improved model for disease ...... sease neuroimaging initiative.
@nl
P2093
P2860
P921
P356
P1476
An improved model for disease ...... sease neuroimaging initiative.
@en
P2093
Allitia Dibernardo
Mahesh N Samtani
Michael Farnum
Nandini Raghavan
Vaibhav Narayan
Victor Lobanov
P2860
P304
P356
10.1177/0091270011405497
P577
2011-06-09T00:00:00Z